AcuCort
Helsingborg
About AcuCort
AcuCort’s vision is that Dexa ODF will be globally commercialized, be well integrated and used in the treatment/risk management of acute allergic reactions and croup in children, and see wide use against chemotherapy-induced nausea and vomiting (CINV.) AcuCort shall develop and commercialize Dexa ODF supported by a global network of licensees and/or distributors. AcuCort shall also identify, develop and commercialize complementary smart products with short time to launch that are based on existing substances. AcuCort AB was founded in 2006 as a subsidiary of DuoCort AB. 2011 marked a new beginning for AcuCort and its development project, as the life science company P.U.L.S. AB acquired the company from DuoCort AB. From then until April 2017 AcuCort has been managed as a part of the PULS group, now known as AQILION AB. Following a successful IPO (Initial Public Offering), AcuCort was listed in Sweden.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Total funding: $103.7K
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2025)
- Ticker: sto:ACUC
- Website: acucort.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care
Canonical: https://fsome.com/organization/acucort-162555 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.